Tan Sven Zcp, Jubouri Matti, Bashir Mohamad
Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
Hull-York Medical School, University of York, York, UK.
Asian Cardiovasc Thorac Ann. 2023 Sep;31(7):589-595. doi: 10.1177/02184923221140756. Epub 2022 Nov 17.
Application of thoracic endovascular aortic repair (TEVAR) to the aortic arch has been met with the development of purpose-made endoprostheses for on-label use in the aortic arch. An appraisal of the clinical efficacy of each major device is therefore useful towards informing clinical decision making for patients eligible for endovascular arch repair (EAR) rather than open surgical reconstruction.
A literature review of publications outlining clinical experience with the RELAY™ Branched and Zenith™ devices was undertaken, and the results therefrom analysed to evaluate the clinical efficacies of each device.
Early- and long-term mortality rates associated with EAR appear favourable, especially compared against open surgical repair. EAR is also associated with good neurological outcomes and target vessel patency rates. However, EAR continues to be associated with substantial reintervention rates.
At the present stage, EAR represents a promising alternative option to open surgical reconstruction in patients that meet its eligibility criteria. Though there remains a substantial learning curve associated with EAR, its favourable outcome profile is likely to increase its applicability in the future.
随着专门用于主动脉弓的定制腔内修复器械的研发,胸主动脉腔内修复术(TEVAR)已应用于主动脉弓。因此,评估每种主要器械的临床疗效有助于为适合腔内主动脉弓修复术(EAR)而非开放手术重建的患者提供临床决策依据。
对概述RELAY™分支型和Zenith™器械临床经验的文献进行综述,并分析结果以评估每种器械的临床疗效。
EAR相关的早期和长期死亡率似乎较低,尤其是与开放手术修复相比。EAR还与良好的神经功能预后和靶血管通畅率相关。然而,EAR仍与较高的再次干预率相关。
现阶段,EAR对符合其适应证的患者而言是开放手术重建的一个有前景的替代选择。尽管EAR仍存在较大的学习曲线,但其良好的预后特征可能会增加其未来的适用性。